Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AU-801
- Development stage
- Preclinical
- Lead developer
- Agenus
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
AU-801 is an investigational drug candidate initially developed by Agenus, Inc. for the potential treatment of immune system diseases. While it is categorized as a monoclonal antibody within Agenus's immunology portfolio, detailed information regarding its specific biological target, mechanism of action, and molecular structure has not been publicly disclosed. The program's development status is currently listed as pending or unknown, and it has not yet advanced into public clinical trial phases. It is likely part of Agenus's early-stage discovery pipeline or a legacy program from its acquisition of 4-Antibody.
Beyond the preview
Go deeper on AU-801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AU-801.